HU0204115D0

Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity

Abstract

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Published
  4. Today

204 members in 32 offices

This recordMember, by publication datePriority claim22 more offices are in the list below

Priority claims6

Priority claims
DocumentOfficeKindDate
59922696United States of AmericaA
59922696United States of AmericaA
3147696United States of AmericaP
3147696United States of AmericaP
US19960031476P–––
US19960599226–––

Members204

Family members, oldest first
DocumentOfficeKind
CA2243459A1CanadaA1
CA2389943A1CanadaA1
CA2596476A1CanadaA1
WO9729131A1World Intellectual Property Organization (WIPO)A1
AU2122997AAustraliaA
NO983627D0NorwayD0
NO20026202LNorwayL
NO20040052LNorwayL
NO20040154LNorwayL
NO983627LNorwayL
MX9806347AMexicoA
CZ247698A3CzechiaA3
TR199801532T2TürkiyeT2
PL328411A1PolandA1
SK106298A3SlovakiaA3
IL125697D0IsraelD0
BR9707379ABrazilA
CN1215407AChinaA
BG102755ABulgariaA
EP0929578A1European Patent Office (EPO)A1
HU1500179A2HungaryA2
HU9901874A2HungaryA2
HUP1500179A2HungaryA2
HUP9901874A2HungaryA2
SI9720020ASloveniaA
KR19990082430ARepublic of KoreaA
HK1019452A1Hong Kong, ChinaA1
HU9901874A3HungaryA3
HUP9901874A3HungaryA3
JP2000507810AJapanA
US6090382AUnited States of AmericaA
AU722077B2AustraliaB2
NZ331579ANew ZealandA
US6258562B1United States of AmericaB1
AU6664900AAustraliaA
SI9720020BSloveniaB
KR100317188B1Republic of KoreaB1
CA2243459CCanadaC
NO20026202D0NorwayD0
US6509015B1United States of AmericaB1
EP1285930A2European Patent Office (EPO)A2
HU0204115D0This recordHungaryD0
HU221984B1HungaryB1
IL151641D0IsraelD0
EP0929578B1European Patent Office (EPO)B1
AT239041TAustriaT
ATE239041T1AustriaT1
US2003092059A1United States of AmericaA1
DE69721548D1GermanyD1
JP2003177130AJapanA
UA57726C2UkraineC2
DK0929578T3DenmarkT3
CZ292465B6CzechiaB6
BG107537ABulgariaA
PT929578EPortugalE
US2003219438A1United States of AmericaA1
ES2198552T3SpainT3
DE69721548T2GermanyT2
NO316711B1NorwayB1
LU91062I2LuxembourgI2
NL300143I1Netherlands (Kingdom of the)I1
CN1504752AChinaA
NL300143I2Netherlands (Kingdom of the)I2
AU2004202769A1AustraliaA1
SK284040B6SlovakiaB6
AU775499B2AustraliaB2
DE122004000004I1GermanyI1
DE122004000003I1GermanyI1
PL188192B1PolandB1
RU2003120859ARussian FederationA
IL125697AIsraelA
HK1066860A1Hong Kong, ChinaA1
RO119831B1RomaniaB1
NZ512006ANew ZealandA
CY2463B1CyprusB1
BG64564B1BulgariaB1
NO319955B1NorwayB1
NO320657B1NorwayB1
RU2268266C2Russian FederationC2
US2006024293A1United States of AmericaA1
RU2270030C2Russian FederationC2
BG109311ABulgariaA
BG64776B1BulgariaB1
AU2004202769B2AustraliaB2
NZ536216ANew ZealandA
RU2005113954ARussian FederationA
NO322755B1NorwayB1
CN1876683AChinaA
AU2006241387A1AustraliaA1
JP3861118B2JapanB2
CN1300173CChinaC
JP2007045828AJapanA
PL193499B1PolandB1
CN1935260AChinaA
DE122004000003I2GermanyI2
US7223394B2United States of AmericaB2
EP1285930A3European Patent Office (EPO)A3
CN101003573AChinaA
US2007249813A1United States of AmericaA1
NO2004002I2NorwayI2
Showing 100 of 204